• No notifications yet.
  • Sign Out
logo image
  • logo image
  • More
Registered User? Login

Welcome to LSPN Connect! 

Join our Community 

Make the most of your membership with our community. Find, message and set up meetings with other members

Forgot Password?
Sign Up
loader image
New User? Sign Up

Welcome to LSPN Connect! 

Join our Community 

Make the most of your membership with our community. Find, message and set up meetings with other members

Forgot Password?
Login
loader image

    Why Patent Protection is key to Commercialising Repurposed Drugs

    Join this complimentary session on April 8 at 5pm BST/12pm ET

    Without patent protection, efforts to commercialise a repurposed drug have little chance for a reasonable return and are unlikely to attract outside investment.  Repurposing drugs can be extremely fruitful for companies as long as proper patent protection is in place.  There are a few barriers to consider when trying to patent protect repurposed drugs:

    • The issue of novelty
    • An obviousness rejection and the use of “unexpected results”
    • “Composition of matter” patent vs “method of use patent”

    Join this panel discussion to discuss these issues, and how best to maximise your return on repurposed drugs. 

    Register below!

    Our Speakers

    speaker image
    JL
    John Liddicoat
    Senior research associate
    University of Cambridge
    speaker image
    JC
    John Conour
    Partner
    MBHB
    speaker image
    DM
    Duane Marks
    Assistant General Patent Counsel
    Eli Lilly and Company
    speaker image
    A
    MaryAnne Armstrong
    partner
    BSKB, LLP
    speaker image
    A
    Pankaj Agarwal
    Principal Computational Biologist
    BioInfi

    Register Now

    Sponsored By

    Partner logo
Contact the organizer
Contact the organizer